文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

吸入氨甲环酸作为危重儿科患者肺出血的新型治疗:一项观察性研究

Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study.
PubMed 文献 · Crit Care Explor · 2020-01-29
一句话结论回顾性观察显示,19例危重儿科肺出血患者中18例(95%)经吸入或气管内滴入氨甲环酸后出血停止,未记录到重大不良事件。

该回顾性观察研究纳入2011至2018年一家独立儿童医院ICU中0至18岁、接受至少一剂吸入或气管内滴入氨甲环酸的儿科患者,共19例。中位年龄72个月(11-187个月),58%为女性,42%有先天性心脏病。出血病因包括弥漫性肺泡出血9例(47%)、主要主肺动脉侧支动脉相关肺出血4例(21%)等。19例中18例(95%)经吸入氨甲环酸后肺出血停止,未记录到重大不良事件。作者认为吸入氨甲环酸可能可安全用于治疗危重儿科患者不同病因的肺出血,但需前瞻性研究确定最佳剂量和给药策略。

要点

  • 19例危重儿科肺出血患者接受吸入或气管内滴入氨甲环酸,18例(95%)出血停止,未记录到重大不良事件。
  • 研究中位年龄72个月(11-187个月),58%为女性,42%有先天性心脏病。
  • 出血病因以弥漫性肺泡出血最多见(9/19,47%),其次为主要主肺动脉侧支动脉相关肺出血(4/19,21%)。
  • 作者认为吸入氨甲环酸可能可安全用于危重儿科患者不同病因的肺出血,但需前瞻性研究确定最佳剂量和给药策略。

适用人群与场景

  • 0至18岁、收入ICU并接受至少一剂吸入或气管内滴入氨甲环酸的儿科患者。
  • 研究场所为一家年ICU收治量超过3500例的独立儿童医院。

处置流程与药物剂量

  • 干预为吸入或气管内滴入氨甲环酸;原文未报告具体剂量、给药频次和疗程。

研究设计与关键结果

  • 回顾性观察研究,2011至2018年,患者随访至出院,共19例纳入。
  • 中位年龄72个月(11-187个月),女性11例(58%),先天性心脏病8例(42%)。
  • 病因:弥漫性肺泡出血9例(47%),主要主肺动脉侧支动脉相关肺出血4例(21%),气道黏膜出血2例(11%),医源性2例(11%),肺栓塞1例,1例病因未明确。
  • 19例中18例(95%)经吸入氨甲环酸后肺出血停止,未记录到重大不良事件。

证据类型、等级与局限

  • 证据类型:回顾性观察研究。
  • 作者指出需在這一脆弱人群中开展前瞻性研究以确定最佳剂量和给药策略,并明确不同病因下的差异效应。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为吸入氨甲环酸可能可安全用于治疗危重儿科患者不同病因的肺出血。
  • 作者指出需前瞻性研究确定最佳剂量和给药策略,以及明确不同病因下的差异效应。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVES: To describe the use of inhaled or endotracheally instilled tranexamic acid in critically ill pediatric patients for the treatment of pulmonary hemorrhage, which can be severe, life-threatening, and include potentially high-risk management procedures.

DESIGN: Retrospective observational study from 2011-2018 with patients followed until hospital discharge.

SETTING: Free-standing children's hospital with an annual ICU volume of more than 3,500 yearly admissions.

PATIENTS: Pediatric patients, ages 0 to 18 years, admitted to an ICU and who received at least one dose of inhaled or endotracheally instilled tranexamic acid were included.

INTERVENTIONS: Inhaled or endotracheally instilled tranexamic acid.

MEASUREMENTS AND MAIN RESULTS: This study described the efficacy and adverse effects of patients who received inhaled or endotracheally instilled tranexamic acid. A total of 19 patients met inclusion criteria; median age was 72 months (11-187 mo), most patients were female (11, 58%), and almost half our patients (8, 42%) had congenital heart disease. Nine of 19 encounters (47%) had diffuse alveolar hemorrhage, four (21%) had pulmonary hemorrhage related to major aortopulmonary collateral arteries, two (11%) had mucosal airway bleeding, two (11%) were iatrogenic, one had a pulmonary embolism, and one patient did not have their etiology of pulmonary hemorrhage determined. Cessation of pulmonary hemorrhage was achieved in 18 of 19 patients (95%) with inhaled tranexamic acid with no major adverse events recorded.

CONCLUSIONS AND RELEVANCE: We demonstrate that inhaled tranexamic acid may be safely used to treat pulmonary hemorrhage from varied etiologies in critically ill pediatric patients. Prospective studies are required in this vulnerable population to determine optimal dosing and delivery strategies, as well as to define any differential effect according to etiology.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. O'Neil ER, Schmees LR, Resendiz K, et al. Inhaled Tranexamic Acid As a Novel Treatment for Pulmonary Hemorrhage in Critically Ill Pediatric Patients: An Observational Study. Crit Care Explor. 2020. PMID: 32166295. doi:10.1097/CCE.0000000000000075

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。